Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer

In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and tumor suppressor STK11 (also known as LKB1) confer an aggressive malignant phenotype, an unfavourability towards immunotherapy, and overall poor prognoses in patients. In a previous study, we showed that murine KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyunmin, Cai, Feng, Kelekar, Neil, Velupally, Nipun K., Kim, Jiyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750012/
https://www.ncbi.nlm.nih.gov/pubmed/35011738
http://dx.doi.org/10.3390/cells11010176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750012/
https://www.ncbi.nlm.nih.gov/pubmed/35011738
http://dx.doi.org/10.3390/cells11010176

Ejemplares similares